Plural Chalcogens Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding Patents (Class 514/425)
-
Publication number: 20100286227Abstract: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.Type: ApplicationFiled: January 28, 2008Publication date: November 11, 2010Applicant: SIMPSON BIOTECH CO., LTD.Inventors: Chia-Chin Sheu, Tun-Tschu Chang, Masao Hattori
-
Publication number: 20100286073Abstract: The present invention relates to compounds, as well as to compositions, methods and kits comprising such compounds, for use in the treatment or prophylaxis of fibromyalgia, chronic fatigue syndrome, myofascial pain syndrome, Gulf War syndrome and related conditions, wherein the compound is a fatty acid oxidation inhibitor and/or a carbohydrate oxidation activator.Type: ApplicationFiled: October 3, 2008Publication date: November 11, 2010Inventor: Paul JENKINS
-
Patent number: 7825268Abstract: Compounds of the Formula I, wherein A1 is O or NH; A2 is O or S; each of R1 and R2 is independently hydrogen, a methyl or C2-C8-saturated or mono- or doubly unsaturated, branched or linear hydrocarbon group; and R3 is a C1-C18-saturated or mono- or doubly unsaturated, branched or linear hydrocarbon group wherein, each of R1, R2 and R3 comprises a heteroatom selected from the group consisting of O and S in the chain and/or is mono- or multiply-substituted by a substituent selected from the group consisting of halogen, hydroxy, C1-C6-alkyl, trifluoromethyl, C1-C6-alkoxy, C6-C10-aryl, and C1-C6-alkyl-C6-C10-aryl are useful for controlling the interaction process between microorganisms such as in the development and/or maturation of biofilms; multicellular swarm behavior; the concerted development of antibiotic resistances; the concerted synthesis of antibiotics; the concerted synthesis of pigments; the concerted production of extracellular enzymes; or the concerted production of virulence factors.Type: GrantFiled: June 22, 2006Date of Patent: November 2, 2010Assignee: Henkel AG & Co. KGaAInventors: Stefan Stumpe, Roland Breves, Ursula Huchel, Frank Janssen, André Hätzelt
-
Publication number: 20100240581Abstract: Methods of modulating chronic low-grade inflammation are provided. More particularly, methods of treating diabetes, such as for example, type-2 diabetes mellitus, in a mammal by administering an effective amount of a selective proteasome inhibitor are provided. Also provided are unit dosage forms of such inhibitors.Type: ApplicationFiled: November 13, 2007Publication date: September 23, 2010Applicant: The Trustees of Columbia University in the City of New YorkInventors: Drew Tortoriello, Stuart P Weisberg
-
Publication number: 20100240643Abstract: The present invention relates to the use of active substance combinations which consist firstly of known cyclic ketoenols and secondly of further known insecticidal active substances, for controlling animal pests from the stink bug family (Pentatomidae).Type: ApplicationFiled: June 17, 2008Publication date: September 23, 2010Applicant: Bayer CropScience AGInventors: Reiner Fischer, Konrad Kemper, Jürgen Kühnhold, Xavier Alain Marie Van Waetermeulen, Francisco Leonel Junior Lozano
-
Publication number: 20100233190Abstract: The present invention provides single chain antibody-directed polymeric prodrugs containing multifunctional linkers. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.Type: ApplicationFiled: March 12, 2009Publication date: September 16, 2010Applicant: ENZON PHARMACEUTICALS, INC.Inventors: Hong ZHAO, Maria Belen RUBIO, Pasanna Reddy
-
Publication number: 20100215574Abstract: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.Type: ApplicationFiled: October 22, 2009Publication date: August 26, 2010Inventor: FELIX KRATZ
-
Publication number: 20100216835Abstract: The present invention provides compositions and methods for modulating bacterial quorum sensing using antagonist or agonist compounds. Further, the present invention provides methods of treating or preventing microbial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.Type: ApplicationFiled: February 25, 2010Publication date: August 26, 2010Inventors: Jo E. Handelsman, Bradley R. Borlee
-
Patent number: 7781391Abstract: The present invention relates to amine functionalized lipophilic compounds and their use in personal care products, particularly those for colored hair.Type: GrantFiled: March 16, 2007Date of Patent: August 24, 2010Assignee: Croda, Inc.Inventors: Robert Comber, Abel G. Pereira
-
Patent number: 7776791Abstract: The invention relates to novel N-heterocyclylphenyl-substituted cyclic ketoenols of the formula (I) in which CKE, W, X, Y and Z are as defined in the disclosure, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides and/or microbicides. The invention further relates to selective herbicidal compositions comprising firstly the N-heterocyclylphenyl-substituted cyclic ketoenols and secondly a compound which improves crop plant tolerance.Type: GrantFiled: June 7, 2004Date of Patent: August 17, 2010Assignee: Bayer CropScience AGInventors: Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Stefan Lehr, Klaus Kunz, Jörg Konze, Olga Malsam, Mark Wilhelm Drewes, Dieter Feucht, Karl-Heinz Kuck, Ulrike Wachendorff-Neumann, Wahed Ahmed Moradi, Guido Bojack, Thomas Auler, Martin Hills, Heinz Kehne
-
Publication number: 20100204162Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.Type: ApplicationFiled: June 26, 2008Publication date: August 12, 2010Inventors: Mary Frances Platt, Emyr Lloyd-Evans, Forbes Dennison Porter
-
Publication number: 20100197702Abstract: The present invention is directed to the provision of ophthalmic compositions such as multi-dose, topical, ophthalmic compositions. The compositions include a nitric oxide (NO) donor compound.Type: ApplicationFiled: January 27, 2010Publication date: August 5, 2010Inventors: Mark R. Hellberg, Peter G. Klimko, Jesse A. May, Suchismita Mohapatra
-
Publication number: 20100189675Abstract: The present invention relates to the cosmetic use of at least one imidopercarboxylic acid derivative in a cosmetic composition comprising a physiologically acceptable medium, as agent for promoting desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal, the associated method of cosmetic treatment and a composition comprising the said imidopercarboxylic acid derivative and a desquamating agent and/or an anti-ageing agent.Type: ApplicationFiled: June 24, 2008Publication date: July 29, 2010Applicant: L'OrealInventor: Pascale Pelletier
-
Publication number: 20100190752Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicant: Gruenenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke, Thomas Christoph
-
Publication number: 20100179211Abstract: The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders.Type: ApplicationFiled: June 4, 2008Publication date: July 15, 2010Applicant: NSAB, FILIAL AF NEUROSEARCH SWEDEN ABInventors: Clas Sonesson, Lars Swanson, Fredrik Pettersson, Nicholas Waters, Susanna Waters
-
3-Biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide
Publication number: 20100173778Abstract: The present invention relates to novel 3-biphenyl-substituted, 3-substituted 4-ketolactams and -lactones of the formula (I) in which A, B, Q, G, W, X, Y and Z are as defined in the disclosure, to processes for their preparation, and to their use as pesticides and/or microbicides and/or herbicides.Type: ApplicationFiled: October 23, 2007Publication date: July 8, 2010Inventors: Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Mark Wilhelm Drewes, Christoph Erdelen, Angelika Lubos-Erdelen, Dieter Feucht, Udo Reckmann, Karl-Heinz Kuck, Ulrike Wachendorff-Neumann -
Publication number: 20100160409Abstract: The invention relates to compounds, which are suitable for coupling to pharmaceuticals, in particular biopharmaceuticals, in addition to conjugates from the compounds comprising biomolecules or pharmaceutically active substances. The inventive compounds are highly cross-linked and can be formed in a simple manner by using a central cross-linking module. The invention also relates to the use of conjugates as an improved formulation of pharmaceuticals and to the production thereof.Type: ApplicationFiled: August 31, 2006Publication date: June 24, 2010Inventors: Ralf Krahmer, Frank Leenders
-
Publication number: 20100152277Abstract: The present invention generally provides a method of measuring the biological activity of diacylglycerol acyltransferase (DGAT). Specifically, the present invention provides a method for rapid, mass screening of compounds which are able to modulate the biological activity of DGAT. More specifically, the present invention provides an assay system for measuring DGAT activity based on the use of particular micelles with the FlashPlate™ technology.Type: ApplicationFiled: December 13, 2005Publication date: June 17, 2010Inventors: Katharina Antonia Germania Josepha Maurita De Waepenaert, Daniëlle Celine Georgette Peeters, Geert Maria Robert Van Hecke, Peter Guido Ida Vermeulen, Monique Jenny Marie Berwaer
-
Publication number: 20100143500Abstract: A method of treating a glial cell related disorder in a mammalian subject includes administering a drug which enhances or prolongs GSK-3 ? or ? inactivation.Type: ApplicationFiled: October 31, 2007Publication date: June 10, 2010Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Sean E. Lawler, Michal Oskar Nowicki, E. Antonio Chiocca
-
Patent number: 7732482Abstract: The present invention relates to novel compounds from Antrodia camphorata and the use thereof.Type: GrantFiled: May 19, 2008Date of Patent: June 8, 2010Assignee: Simpson Biotech Co., Ltd.Inventors: Masao Hattori, Chia-Chin Sheu, Coolin Yang
-
Publication number: 20100137229Abstract: A method of enhancing the activity of lysosomal ?-Galactosidase A (?-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.Type: ApplicationFiled: November 23, 2009Publication date: June 3, 2010Inventors: Jian-Qiang Fan, Satoshi Ishii
-
Publication number: 20100137365Abstract: Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C8-C16 alkyl group. The long chain N-alkyl compounds and oxa-substituted derivatives thereof can be used in the treatment of viral infections, in particular hepatitis B virus or hepatitis C virus, in a cell or an individual. For example, the long chain N-alkyl compounds or oxa-substituted derivatives thereof can be derived from piperidines, pyrrolidines, phenylamines, pyridines, pyrroles, or amino acids.Type: ApplicationFiled: January 28, 2010Publication date: June 3, 2010Inventors: Nicole Zitzmann, Terry D. Butters, Frances M. Platt, Gary S. Jacob, Donald H. Picker, Sandra Carrouee, George W.J. Fleet, Raymond A. Dwek, David Durantel, Anand Mehta, Timothy M. Block
-
Patent number: 7727933Abstract: The invention relates to novel 2-ethyl-4,6-dimethylphenyl-substituted spirocyclic tetramic acid derivatives of the formula (I) in which A, B and G are as defined above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides, and also to selective herbicidal compositions comprising firstly the 2-ethyl-4,6-dimethylphenyl-substituted spirocyclic tetramic acid derivatives of the formula (I) (where G may also be hydrogen) and secondly at least one crop plant compatibility-improving compound.Type: GrantFiled: November 9, 2004Date of Patent: June 1, 2010Assignee: Bayer CropScience AGInventors: Reiner Fischer, Stefan Lehr, Mark Wilhelm Drewes, Christoph Erdelen, Angelika Lubos-Erdelen, legal representative, Dieter Feucht, Jörg Konze, Peter Lösel, Olga Malsam, Guido Bojack, Christian Arnold, Thomas Auler, Martin Jeffrey Hills, Heinz Kehne, Christopher Hugh Rosinger
-
Publication number: 20100130584Abstract: Compounds isolated from the fruiting body of A. camphorata in a solid culture or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: November 21, 2008Publication date: May 27, 2010Applicant: Well Shine Biotechnology Development Co., Ltd.Inventors: Yueh-Hsiung Kuo, Bi-Fong Lin
-
Publication number: 20100130574Abstract: This invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1.Type: ApplicationFiled: September 30, 2009Publication date: May 27, 2010Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Kevin Eggan, Francesco Paolo DiGiorgio
-
Patent number: 7718186Abstract: The invention relates to novel 2-alkoxy-6-alkylphenyl-substituted spirocyclic tetramic acid derivatives of the formula (I) in which A, B, D, G, X, Y and Z are as defined above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides, and also to selective herbicidal compositions comprising, firstly, the 2-alkoxy-6-alkylphenyl-substituted spirocyclic tetramic acid derivatives of the formula (I) and, secondly, at least one crop plant tolerance promoter compound.Type: GrantFiled: October 21, 2005Date of Patent: May 18, 2010Assignee: Bayer CropScience AGInventors: Reiner Fischer, Stefan Lehr, Mark Wilhelm Drewes, Dieter Feucht, Olga Malsam, Guido Bojack, Christian Arnold, Thomas Auler, Martin Jeffrey Hills, Heinz Kehne, Chris Rosinger
-
Publication number: 20100113477Abstract: The present invention provides aryl- or heteroaryl-diketo acid compounds effective to inhibit an activity of a Mycobacterial malate synthase enzyme or to inhibit a malate synthase activity in other bacteria having the enzyme. The compounds may be phenyl-naphthyl-, or thienyl-substituted diketo acids and carboxylate derivatives thereof. Also provided are methods of treating tuberculosis or other pathophysiological conditions associated with a malate synthase enzyme with the inhibitory compounds and methods of in silico design of the inhibitory compounds. In addition, the present invention provides the inhibitory compounds designed by this method. Furthermore, three-dimensional X-ray crystal structures of the Mycobacterial malate synthase complexed with the inhibitory compounds are provided. Further still a method for stabilizing an aromatic or heteroaromatic diketo acid or its prodrug or close analog in solution by derivatizing at least the ortho position on the aromatic ring is provided.Type: ApplicationFiled: October 20, 2009Publication date: May 6, 2010Inventors: Joel S. Freundlich, James C. Sacchettini, Inna V. Kriger, Thomas R. Ioerger, Vijay Gawandi
-
Patent number: 7709516Abstract: Compounds having the structure (or their salts): are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.Type: GrantFiled: June 14, 2006Date of Patent: May 4, 2010Assignee: Endorecherche, Inc.Inventors: Fernand Labrie, Rock Breton, Shankar Mohan Singh, René Maltais
-
Patent number: 7705037Abstract: The present invention relates to compounds of formula (I). These compounds are a novel type of peptide deformylase (PDF) inhibitors, and are therefore of great interest especially as new antibiotics.Type: GrantFiled: June 6, 2006Date of Patent: April 27, 2010Assignee: Novartis AGInventor: Michael Thormann
-
Publication number: 20100099736Abstract: The invention discloses the use of a compound of formula (I), wherein R1, R2, R3, and R4 each independently represents: hydrogen; halo; hydroxy; (C1-C6) alkyl optionally substituted by hydroxy or (C1-C4) alkoxy; (C1-C6) haloalkyl; (C1-C6) alkoxy; and (C1-C6) haloalkoxy; for the preparation of a medicament for the prevention and/or treatment of diseases resulting from opening of the MPTP which are characterized by degenerative tissue damages, in particular, diabetes and diabetic complications, neurological diseases and stroke, heart infarction, inherited dystrophies and hepatitis, more particularly, diabetic vascular diseases, such as diabetic retinopathy, and neurodegenerative disorders, such as multiple sclerosis. Further objects are a group of selected individual compounds of formula (I) for use as medicaments and a further group of selected individual compounds of formula (I) as novel compounds.Type: ApplicationFiled: September 21, 2007Publication date: April 22, 2010Applicant: Congenia S.R.L.Inventors: PierGiuseppe Pellicci, Marco Giorgio, Saverio Minucci, Paolo Bernardi, Gilles Pain, Stephen Martin Courtney, Christopher John Yarnold, Joachim Kraemer
-
Publication number: 20100048650Abstract: The present invention relates to methods and compositions for modulating the activity of two-pore domain K+ channels (“K2P channels”) as a means for inducing preconditioning protection. Such preconditioning can be used to reduce the effect of ischemia associated with ischemic heart disease, myocardial infarcation or cardiac surgery. The invention is based on the discovery that the myoprotective current induced by short periods of ischemia is carried by a non-classical two-pore domain K+ channel.Type: ApplicationFiled: April 4, 2007Publication date: February 25, 2010Inventors: Ira S. Cohen, Zhongju Lu, Irvin Krukenkamp, Peter R. Brink, Richard B. Robinson, Steven J. Feinmark
-
Publication number: 20100022615Abstract: Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions.Type: ApplicationFiled: September 14, 2007Publication date: January 28, 2010Applicant: Onconova Therapeutics, IncInventors: Glenn Fegley, Stanley C. Bell, Stephen Cosenza, Jodie Duke, Reddy H. Premkumar, Reddy M. V. Ramana
-
Publication number: 20090325868Abstract: Provided herein are methods of treating a cancer in a subject comprising administering a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Methods of altering a phenotype of a cancer cell or tumor cell, methods of inhibiting growth of such cells, and methods of inducing apoptosis of these cells are also provided herein. These methods comprise contacting the cell with a FOXP3 protein, a nucleic acid encoding a FOXP3 protein, or an inducing compound which induces FOXP3 protein expression. Further provided herein are diagnostic methods, comprising comparing the expression or structure of a FOXP3 protein or FOXP3 gene in a test sample to that of a normal or prior sample. A method of screening a test compound for anti-cancer activity comprising administering to cells the test compound and measuring FOXP3 protein or FOXP3 gene expression is moreover provided herein.Type: ApplicationFiled: May 12, 2008Publication date: December 31, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Yang Liu, Pan Zheng, Xing Chang, Lizhong Wang, Runhua Liu, Yin Wang, Yan Liu, Tao Zuo
-
Publication number: 20090318515Abstract: The invention provides a method for treating ocular disorders associated with ocular hypertension by administrating an effective amount of a pharmaceutical composition comprising a succinimide derivative.Type: ApplicationFiled: November 14, 2006Publication date: December 24, 2009Inventor: Mordechai Sharir
-
Publication number: 20090305891Abstract: The disclosure relates to novel cycloalkylphenyl-substituted cyclic ketoenols of the formula (I) in which J, X, Y, m and CKE are as defined above, to processes and intermediates for their preparation and to their use as pesticides and/or herbicides. Moreover, the disclosure relates to selective herbicidal compositions comprising, firstly, the cycloalkylphenyl-substituted cyclic ketoenols and, secondly, a crop plant compatibility-improving compound. The disclosure furthermore relates to increasing the activity of crop protection compositions comprising compounds of the formula (I) by adding ammonium or phosphonium salts and, if appropriate, penetrants.Type: ApplicationFiled: February 8, 2007Publication date: December 10, 2009Applicant: Bayer CropScience AGInventors: Reiner Fischer, Thomas Bretschneider, Stefan Lehr, Dieter Feucht, Eva-Maria Franken, Olga Malsam, Alfred Angermann, Guido Bojack, Christian Arnold, Martin Jeffrey Hills, Heinz Kehne, Christopher Hugh Rosinger
-
Publication number: 20090306174Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.Type: ApplicationFiled: December 5, 2006Publication date: December 10, 2009Applicant: Academia SinicaInventors: Pi-Hui Liang, Yi-Ling Lin, Chi-Huey Wong
-
Publication number: 20090298828Abstract: The invention relates to new alkoxyalkyl-substituted cyclic ketoenols of the formula (I) in which A, B, D, G, W, X, Y and Z have the definitions indicated above, to a number of processes and intermediates for their preparation, and to their use as pesticides and/or herbicides and/or microbicides. The invention further provides selectively herbicidal, compositions which comprise alkoxyalkyl-substituted cyclic ketoenols on the one hand and a crop plant tolerance promoter compound on the other. The invention further relates to the boosting of the action of crop protection compositions comprising compounds of the formula (I) through the additions of ammonium salts or phosphonium salts and optionally penetration promoters.Type: ApplicationFiled: May 23, 2007Publication date: December 3, 2009Applicant: BAYER CROPSCIENCE AGInventors: Reiner Fischer, Stefan Lehr, Dieter Feucht, Olga Malsam, Christian Arnold, Martin Jeffrey Hills, Heinz Kehne, Christopher Hugh Rosinger, Rolf Pontzen, Ulrich Görgens, Jan Dittgen
-
Patent number: 7625949Abstract: The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R1-R5, R11c and X1 are as defined herein.Type: GrantFiled: April 22, 2005Date of Patent: December 1, 2009Assignee: Roche Palo Alto LLCInventors: James Patrick Dunn, Donald Roy Hirschfeld, Tania Silva, Zachary Kevin Sweeney, Harit Vora
-
Publication number: 20090275630Abstract: Composition containing, in a physiologically acceptable medium, at least one imidopercarboxylic acid compound and at least one N-acylated amino acid ester of formula (A) as described herein.Type: ApplicationFiled: March 20, 2009Publication date: November 5, 2009Applicant: L'OREALInventors: Roxane Provost, Geoffroy Remaut, Cecile Kermorvan, Celine Moussay
-
Publication number: 20090253669Abstract: Substituted sulfonamide compounds corresponding to the formula I: processes for the preparation thereof, pharmaceutical composition containing these compounds and the use of substituted sulfonamide compounds for the preparation of pharmaceutical compositions.Type: ApplicationFiled: March 16, 2009Publication date: October 8, 2009Applicant: GRUENENTHAL GmbHInventors: Stefan OBERBOERSCH, Melanie REICH, Bernd SUNDERMANN, Werner ENGLBERGER, Sabine HEES, Ruth JOSTOCK, Stefan SCHUNK, Edward BIJSTERVELD, Fritz THEIL
-
Publication number: 20090253672Abstract: This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3, R4, R5, R6, R7, X and Y are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsms K L, S and B These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritisType: ApplicationFiled: October 10, 2006Publication date: October 8, 2009Inventors: Serge Leger, Christopher Bayly, Jean-Francois Truchon
-
Publication number: 20090239885Abstract: The present invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5?-methylthioadenosine phosphorylases (MTAP), 5?-methylthioadenosine nucleosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.Type: ApplicationFiled: June 3, 2009Publication date: September 24, 2009Inventors: Gary Brian Evans, Richard Hubert Furneax, Dirk Henning Lenz, Vern L. Schramm, Peter Charles Tyler, Olga Vladimirovna Zubkova
-
Publication number: 20090239830Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.Type: ApplicationFiled: June 2, 2008Publication date: September 24, 2009Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
-
Publication number: 20090227563Abstract: The present invention concerns boosting the activity of crop protection materials comprising active ingredients from the class of the phenyl-substituted cyclic ketoenols through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium salts and/or phosphonium salts and penetrants, the corresponding materials, processes for preparing them, and their use in crop protection.Type: ApplicationFiled: December 11, 2006Publication date: September 10, 2009Applicant: Bayer CropScience AGInventors: Reiner Fischer, Stefan Lehr, Dieter Feucht, Udo Bickers, Hans Philipp Huff, Erwin Hacker, Rainer Süssmann
-
Publication number: 20090202573Abstract: The present invention provides polymeric conjugates containing positively charged moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.Type: ApplicationFiled: March 12, 2009Publication date: August 13, 2009Applicant: ENZON PHARMACEUTICALS, INC.Inventors: Hong ZHAO, Prasanna REDDY, Ivan HORAK, Jing XIA
-
Publication number: 20090176782Abstract: The present invention relates to compounds that inhibit TACE, compositions thereof, and methods of using those compounds and compositions for treating diseases.Type: ApplicationFiled: November 12, 2008Publication date: July 9, 2009Inventors: Upul Bandarage, Jon Come, Emanuele Perola, Govinda Rao Bhisetti, Jeffrey O. Saunders, Shi Kai Tian, Tiansheng Wang
-
Publication number: 20090176861Abstract: The present invention relates to a novel class of compounds mainly, substituted leucinamide-carboxylate derivatives of formula (I) wherein X is O or NR9, Y is CR1R2, —SO2, C?O or NR9; Z is CR1R2, O, S, —SO2 or NR9 and each G is independently a CR1CR2 and pharmaceutical compositions thereof. Said compounds are cathepsin cysteine protease inhibitors, including but not limited to, inhibitors of cathepsin K, L, S and B. These compounds are useful for treating and preventing cathepsin dependent conditions in which inhibition of bone resorption is indicated, such as osteoporosis.Type: ApplicationFiled: January 6, 2005Publication date: July 9, 2009Inventors: Christopher Bayly, Sheldon N. Crane, Serge Leger
-
Publication number: 20090156614Abstract: This invention provides new compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, prostate cancer, muscle wasting diseases and/or disorders or a bone-related diseases and/or disorders.Type: ApplicationFiled: July 19, 2007Publication date: June 18, 2009Inventors: James T. Dalton, Duane D. Miller, Igor Rakov, Casey Bohl, Michael L. Mohler
-
Patent number: 7544709Abstract: The invention relates to compounds of general formula (I), to a method for the production thereof, to pharmaceutical compositions containing them, and to their use in the treatment and/or prophlaxis of diseases in humans or animals, particularly bacterial infections diseases. The compounds are derivatives of the natural substances andrimide and moiramide B.Type: GrantFiled: November 7, 2002Date of Patent: June 9, 2009Assignee: Bayer Healthcare AGInventors: Nina Brunner, Christoph Freiberg, Thomas Lampe, Ben Newton, Michael Otteneder, Josef Pernerstorfer, Jens Pohlmann, Guido Schiffer, Mitsuyuki Shimada
-
METHOD FOR TREATING CENTRAL PAIN SYNDROM OR FOR INDUCING CENTRALLY GENERATED PAIN IN AN ANIMAL MODEL
Publication number: 20090143450Abstract: The present invention provides a method for treating central pain syndrome in a mammal by administering an effective amount of a thalamic anticonvulsant compound. Also provided are methods for inducing centrally generated pain responses in an animal model and for screening and identifying a compound that inhibits T-type calcium channels.Type: ApplicationFiled: May 5, 2006Publication date: June 4, 2009Applicant: UNIVERSITY OF MARYLAND, BALTIMOREInventor: Scott Thompson